{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:33:30Z","timestamp":1776396810572,"version":"3.51.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>Dupuytren\u2019s contracture (DC) is a chronic debilitating fibroproliferative disorder.<\/jats:p>\n                <jats:p>Common treatment options include collagenase clostridium histolyticum injections (CI), percutaneous needle fasciotomy (NF) and limited fasciectomy (LF). Superiority of one specific treatment remains controversial. This study aims to assess the short-term efficacy and safety of CI, NF, and LF for the treatment of DC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included randomized controlled trials of CI compared with placebo, NF and LF for patients with DC. PubMed, Embase and the Cochrane Library were searched from inception to August 2021. Contracture reduction rates in treated joints (within 0\u20135\u00b0 of full extension within 30\u00a0days), relative reduction in total passive extension deficit (TPED), occurrence of one or more adverse events and number of treatment-related adverse events per patient were the outcomes of interest. The Cochrane risk-of-bias tool was employed for quality assessment of the studies. A network meta-analysis was performed using MetaXL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nine studies met our inclusion criteria (<jats:italic>n<\/jats:italic>\u2009=\u2009903). Overall, risk bias was mixed and mostly low. Short term TPED reduction achieved with LF was superior compared to CI and NF. Although CI achieved greater TPED reduction compared to NF, it was associated with the highest risk of overall adverse effects. The analyzed data was limited to a maximum three-year follow-up period and therefore insufficient for long-term outcome evaluation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In DC, LF may be able to provide patients with severe disease, superior flexion contracture release postoperatively. CI is a valid treatment alternative to NF, however the higher risk of overall adverse effects must be considered. The quality-of-evidence is limited due to short-term follow-up periods and a lack of standardized definitions of complications and adverse events.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-022-05894-6","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T09:13:25Z","timestamp":1666948405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciectomy in the treatment of Dupuytren\u2019s contracture: a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"23","author":[{"given":"Doha","family":"Obed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Salim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Schlottmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alperen S.","family":"Bingoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana C.","family":"Panayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Dastagir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soeren","family":"Koenneker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"issue":"9","key":"5894_CR1","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1358\/dot.2011.47.9.1656502","volume":"47","author":"FTD Kaplan","year":"2011","unstructured":"Kaplan FTD. Collagenase clostridium histolyticum injection for the treatment of Dupuytren\u2019s contracture. Drugs Today. 2011;47(9):653. https:\/\/doi.org\/10.1358\/dot.2011.47.9.1656502.","journal-title":"Drugs Today"},{"issue":"9","key":"5894_CR2","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1302\/0301-620X.100B9.BJJ-2017-1194.R2","volume":"100-B","author":"E Soreide","year":"2018","unstructured":"Soreide E, Murad MH, Denbeigh JM, et al. Treatment of Dupuytren\u2019s contracture: a systematic review. Bone Jt J. 2018;100-B(9):1138\u201345. https:\/\/doi.org\/10.1302\/0301-620X.100B9.BJJ-2017-1194.R2.","journal-title":"Bone Jt J"},{"issue":"5","key":"5894_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/cge.12410","volume":"87","author":"K Becker","year":"2015","unstructured":"Becker K, Tinschert S, Lienert A, et al. The importance of genetic susceptibility in Dupuytren\u2019s disease: genetic susceptibility in Dupuytren\u2019s disease. Clin Genet. 2015;87(5):483\u20137. https:\/\/doi.org\/10.1111\/cge.12410.","journal-title":"Clin Genet"},{"issue":"1","key":"5894_CR4","doi-asserted-by":"publisher","first-page":"14669","DOI":"10.1038\/s41598-021-94025-7","volume":"11","author":"M Rydberg","year":"2021","unstructured":"Rydberg M, Zimmerman M, L\u00f6fgren JP, et al. Metabolic factors and the risk of Dupuytren\u2019s disease: data from 30,000 individuals followed for over 20 years. Sci Rep. 2021;11(1):14669. https:\/\/doi.org\/10.1038\/s41598-021-94025-7.","journal-title":"Sci Rep"},{"issue":"1","key":"5894_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00776-013-0478-y","volume":"19","author":"T Tajika","year":"2014","unstructured":"Tajika T, Kobayashi T, Kaneko T, et al. Epidemiological study for personal risk factors and quality of life related to Dupuytren\u2019s disease in a mountain village of Japan. J Orthop Sci Off J Jpn Orthop Assoc. 2014;19(1):64\u201370. https:\/\/doi.org\/10.1007\/s00776-013-0478-y.","journal-title":"J Orthop Sci Off J Jpn Orthop Assoc"},{"issue":"1","key":"5894_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13018-020-01999-7","volume":"15","author":"N Salari","year":"2020","unstructured":"Salari N, Heydari M, Hassanabadi M, et al. The worldwide prevalence of the Dupuytren disease: a comprehensive systematic review and meta-analysis. J Orthop Surg. 2020;15(1):495. https:\/\/doi.org\/10.1186\/s13018-020-01999-7.","journal-title":"J Orthop Surg"},{"issue":"2","key":"5894_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00238-018-1490-4","volume":"42","author":"R Leung","year":"2019","unstructured":"Leung R, Capstick R, Lei A, Nour D, Rozen WM, Hunter-Smith DJ. Morbidity of interventions in previously untreated Dupuytren disease: a systematic review. Eur J Plast Surg. 2019;42(2):111\u20138. https:\/\/doi.org\/10.1007\/s00238-018-1490-4.","journal-title":"Eur J Plast Surg"},{"issue":"1","key":"5894_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12178-012-9148-5","volume":"6","author":"S Lo","year":"2013","unstructured":"Lo S, Pickford M. Current concepts in Dupuytren\u2019s disease. Curr Rev Musculoskelet Med. 2013;6(1):26\u201334. https:\/\/doi.org\/10.1007\/s12178-012-9148-5.","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"5","key":"5894_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1753193420903624","volume":"45","author":"M Karpinski","year":"2020","unstructured":"Karpinski M, Moltaji S, Baxter C, Murphy J, Petropoulos JA, Thoma A. A systematic review identifying outcomes and outcome measures in Dupuytren\u2019s disease research. J Hand Surg Eur. 2020;45(5):513\u201320. https:\/\/doi.org\/10.1177\/1753193420903624.","journal-title":"J Hand Surg Eur"},{"key":"5894_CR10","doi-asserted-by":"publisher","unstructured":"Rodrigues JN, Becker GW, Ball C, et al. Surgery for Dupuytren\u2019s contracture of the fingers. Cochrane Musculoskeletal Group, ed. Cochrane Database Syst Rev. 2015;2015(12). https:\/\/doi.org\/10.1002\/14651858.CD010143.pub2","DOI":"10.1002\/14651858.CD010143.pub2"},{"issue":"2","key":"5894_CR11","doi-asserted-by":"publisher","first-page":"230949902092174","DOI":"10.1177\/2309499020921747","volume":"28","author":"TB Cooper","year":"2020","unstructured":"Cooper TB, Poonit K, Yao C, Jin Z, Zheng J, Yan H. The efficacies and limitations of fasciectomy and collagenase clostridium histolyticum in Dupuytren\u2019s contracture management: a meta-analysis. J Orthop Surg. 2020;28(2):230949902092174. https:\/\/doi.org\/10.1177\/2309499020921747.","journal-title":"J Orthop Surg"},{"issue":"10","key":"5894_CR12","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005.","journal-title":"J Clin Epidemiol"},{"issue":"oct18 2","key":"5894_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928\u2013d5928. https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"issue":"4","key":"5894_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/XEB.0000000000000140","volume":"16","author":"SAR Doi","year":"2018","unstructured":"Doi SAR, Barendregt JJ. A generalized pairwise modelling framework for network meta-analysis. Int J Evid Based Healthc. 2018;16(4):187\u201394. https:\/\/doi.org\/10.1097\/XEB.0000000000000140.","journal-title":"Int J Evid Based Healthc"},{"key":"5894_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cct.2015.05.009","volume":"45","author":"SAR Doi","year":"2015","unstructured":"Doi SAR, Barendregt JJ, Khan S, Thalib L, Williams GM. Advances in the meta-analysis of heterogeneous clinical trials I: the inverse variance heterogeneity model. Contemp Clin Trials. 2015;45:130\u20138. https:\/\/doi.org\/10.1016\/j.cct.2015.05.009.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"5894_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15(1):58. https:\/\/doi.org\/10.1186\/s12874-015-0060-8.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"5894_CR17","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/PRS.0000000000006828","volume":"145","author":"Y Abe","year":"2020","unstructured":"Abe Y. Comparison of treatment outcomes after collagenase injection and percutaneous needle fasciotomy for Dupuytren\u2019s contracture: objective and subjective comparisons with a 3-year follow-up. Plast Reconstr Surg. 2020;145(6):1464\u201374. https:\/\/doi.org\/10.1097\/PRS.0000000000006828.","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"5894_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jhsa.2007.04.002","volume":"32","author":"MA Badalamente","year":"2007","unstructured":"Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren\u2019s contracture. J Hand Surg. 2007;32(6):767\u201374. https:\/\/doi.org\/10.1016\/j.jhsa.2007.04.002.","journal-title":"J Hand Surg"},{"issue":"5","key":"5894_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/jhsu.2002.35299","volume":"27","author":"MA Badalamente","year":"2002","unstructured":"Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren\u2019s disease. J Hand Surg. 2002;27(5):788\u201398. https:\/\/doi.org\/10.1053\/jhsu.2002.35299.","journal-title":"J Hand Surg"},{"issue":"12","key":"5894_CR20","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.jhsa.2010.08.007","volume":"35","author":"D Gilpin","year":"2010","unstructured":"Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren\u2019s disease. J Hand Surg. 2010;35(12):2027-2038.e1. https:\/\/doi.org\/10.1016\/j.jhsa.2010.08.007.","journal-title":"J Hand Surg"},{"issue":"10","key":"5894_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1056\/NEJMoa0810866","volume":"361","author":"LC Hurst","year":"2009","unstructured":"Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren\u2019s contracture. N Engl J Med. 2009;361(10):968\u201379. https:\/\/doi.org\/10.1056\/NEJMoa0810866.","journal-title":"N Engl J Med"},{"issue":"6","key":"5894_CR22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/1753193415617385","volume":"41","author":"P Scherman","year":"2016","unstructured":"Scherman P, Jenmalm P, Dahlin LB. One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren\u2019s contracture: a two-centre prospective randomized clinical trial. J Hand Surg Eur. 2016;41(6):577\u201382. https:\/\/doi.org\/10.1177\/1753193415617385.","journal-title":"J Hand Surg Eur"},{"issue":"5","key":"5894_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jhsa.2017.03.003","volume":"42","author":"ST Skov","year":"2017","unstructured":"Skov ST, Bisgaard T, S\u00f8ndergaard P, Lange J. Injectable collagenase versus percutaneous needle fasciotomy for Dupuytren contracture in proximal interphalangeal joints: a randomized controlled trial. J Hand Surg. 2017;42(5):321-328.e3. https:\/\/doi.org\/10.1016\/j.jhsa.2017.03.003.","journal-title":"J Hand Surg"},{"issue":"9","key":"5894_CR24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jhsa.2016.06.014","volume":"41","author":"J Str\u00f6mberg","year":"2016","unstructured":"Str\u00f6mberg J, Ibsen-S\u00f6rensen A, Frid\u00e9n J. Comparison of treatment outcome after collagenase and needle fasciotomy for Dupuytren contracture: a randomized, single-blinded, clinical trial with a 1-year follow-up. J Hand Surg. 2016;41(9):873\u201380. https:\/\/doi.org\/10.1016\/j.jhsa.2016.06.014.","journal-title":"J Hand Surg"},{"issue":"5","key":"5894_CR25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jhsa.2006.02.021","volume":"31","author":"AL van Rijssen","year":"2006","unstructured":"van Rijssen AL, Gerbrandy FSJ, Linden HT, Klip H, Werker PMN. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren\u2019s disease: a 6-week follow-up study. J Hand Surg. 2006;31(5):717\u201325. https:\/\/doi.org\/10.1016\/j.jhsa.2006.02.021.","journal-title":"J Hand Surg"},{"issue":"6","key":"5894_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2146\/news100019","volume":"67","author":"K Traynor","year":"2010","unstructured":"Traynor K. Enzyme product approved for rare hand disorder. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 2010;67(6):416. https:\/\/doi.org\/10.2146\/news100019.","journal-title":"Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm"},{"issue":"5","key":"5894_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2019.11.019","volume":"77","author":"A Cocci","year":"2020","unstructured":"Cocci A, Russo GI, Salamanca JIM, Ralph D, Palmieri A, Mondaini N. The end of an era: withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European Market. Eur Urol. 2020;77(5):660\u20131. https:\/\/doi.org\/10.1016\/j.eururo.2019.11.019.","journal-title":"Eur Urol"},{"issue":"3","key":"5894_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1055\/s-0040-1721876","volume":"13","author":"T Hirase","year":"2021","unstructured":"Hirase T, Suresh R, Cotton MO, et al. Percutaneous needle fasciotomy versus collagenase injection for Dupuytren\u2019s Contracture: a systematic review of comparative studies. J Hand Microsurg. 2021;13(3):150\u20136. https:\/\/doi.org\/10.1055\/s-0040-1721876.","journal-title":"J Hand Microsurg"},{"issue":"1","key":"5894_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/PRS.0000000000001320","volume":"136","author":"C Zhou","year":"2015","unstructured":"Zhou C, Hovius SER, Slijper HP, et al. Collagenase clostridium histolyticum versus limited fasciectomy for Dupuytren\u2019s Contracture: Outcomes from a Multicenter Propensity Score Matched Study. Plast Reconstr Surg. 2015;136(1):87\u201397. https:\/\/doi.org\/10.1097\/PRS.0000000000001320.","journal-title":"Plast Reconstr Surg"},{"issue":"4","key":"5894_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11552-013-9540-7","volume":"8","author":"NH Naam","year":"2013","unstructured":"Naam NH. Functional outcome of collagenase injections compared with fasciectomy in treatment of Dupuytren\u2019s contracture. Hand N Y N. 2013;8(4):410\u20136. https:\/\/doi.org\/10.1007\/s11552-013-9540-7.","journal-title":"Hand N Y N"},{"issue":"11","key":"5894_CR31","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1007\/s00402-018-3034-6","volume":"138","author":"FM Lecl\u00e8re","year":"2018","unstructured":"Lecl\u00e8re FM, Kohl S, Varonier C, Unglaub F, V\u00f6gelin E. Range of motion, postoperative rehabilitation and patient satisfaction in MCP and PIP joints affected by Dupuytren Tubiana stage 1\u20133: collagenase enzymatic fasciotomy or limited fasciectomy? A clinical study in 52 patients. Arch Orthop Trauma Surg. 2018;138(11):1623\u201331. https:\/\/doi.org\/10.1007\/s00402-018-3034-6.","journal-title":"Arch Orthop Trauma Surg"},{"issue":"3","key":"5894_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.hcl.2018.03.007","volume":"34","author":"KR Eberlin","year":"2018","unstructured":"Eberlin KR, Mudgal CS. Complications of treatment for Dupuytren disease. Hand Clin. 2018;34(3):387\u201394. https:\/\/doi.org\/10.1016\/j.hcl.2018.03.007.","journal-title":"Hand Clin"},{"issue":"2","key":"5894_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/1753193414528843","volume":"40","author":"CA Peimer","year":"2015","unstructured":"Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren\u2019s contracture. J Hand Surg Eur Vol. 2015;40(2):141\u20139. https:\/\/doi.org\/10.1177\/1753193414528843.","journal-title":"J Hand Surg Eur Vol"},{"issue":"1","key":"5894_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1302\/0301-620X.100B1.BJJ-2017-0463.R1","volume":"100-B","author":"R Sanjuan-Cerver\u00f3","year":"2018","unstructured":"Sanjuan-Cerver\u00f3 R, Carrera-Hueso FJ, Vazquez-Ferreiro P, Ramon-Barrios MA. Efficacy and adverse effects of collagenase use in the treatment of Dupuytren\u2019s disease: a meta-analysis. Bone Jt J. 2018;100-B(1):73\u201380. https:\/\/doi.org\/10.1302\/0301-620X.100B1.BJJ-2017-0463.R1.","journal-title":"Bone Jt J"},{"issue":"5","key":"5894_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.hansur.2017.07.002","volume":"36","author":"C Krefter","year":"2017","unstructured":"Krefter C, Marks M, Hensler S, Herren DB, Calcagni M. Complications after treating Dupuytren\u2019s disease. A systematic literature review. Hand Surg Rehabil. 2017;36(5):322\u20139. https:\/\/doi.org\/10.1016\/j.hansur.2017.07.002.","journal-title":"Hand Surg Rehabil"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-022-05894-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T09:13:32Z","timestamp":1666948412000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-022-05894-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5894"],"URL":"https:\/\/doi.org\/10.1186\/s12891-022-05894-6","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"26 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"939"}}